Contact Congress about H.R. 3375: Fair Prescription Drug Prices for Americans Act

Many U.S. drug list prices could not be higher than the average price in Canada, France, Germany, Italy, Japan, and the United Kingdom. Drug makers would report prices each year, and companies that charge too much would pay fines.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Fair Prescription Drug Prices for Americans Act is a House bill in committee. The latest recorded action: Referred to the House Committee on Energy and Commerce.

Latest action on H.R. 3375: Referred to the House Committee on Energy and Commerce.

Who this affects: This bill mainly affects drug and biologic manufacturers because it limits what they can list as the U.S. retail price for covered products. It could also affect patients, insurers, employers, and government health programs when their costs are tied to list prices. The Department of Health and Human Services would take on new work to collect price reports, calculate the cap, write rules, and enforce fines.

Why this matters: This bill matters because many U.S. drug list prices can be higher than prices in other wealthy countries. It would tie many U.S. prices to a six-country average and punish companies that go above it. That could lower some list prices, but the full effect is uncertain. The bill does not spell out how it would affect rebates, drug availability, insurance premiums, or research spending.

Key provisions in H.R. 3375

• Many covered drugs could not have a higher U.S. retail list price than the foreign average. The average would use prices from Canada, France, Germany, Italy, Japan, and the United Kingdom.
• The bill covers many FDA-approved prescription drugs. It also covers biologic medicines licensed under federal public health law, including products approved through full and follow-on biologic pathways.
• Health and Human Services would calculate the foreign average price every year. The agency would do this for each covered drug and biologic.
• Drug makers would send Health and Human Services a price report each year. The report must list the product's price in the United States and in each of the six countries.
• Health and Human Services could use public records from the six countries to check the reports. This lets the agency add outside price data when needed.

How Modern Action helps you take action on H.R. 3375

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 3375

What is H.R. 3375?

Many U.S. drug list prices could not be higher than the average price in Canada, France, Germany, Italy, Japan, and the United Kingdom. Drug makers would report prices each year, and companies that charge too much would pay fines.

How do I support or oppose H.R. 3375?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about H.R. 3375?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain H.R. 3375 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.